Novel polyglutamine model uncouples proteotoxicity from aging
- PMID: 24817148
- PMCID: PMC4016013
- DOI: 10.1371/journal.pone.0096835
Novel polyglutamine model uncouples proteotoxicity from aging
Abstract
Polyglutamine expansions in certain proteins are the genetic determinants for nine distinct progressive neurodegenerative disorders and resultant age-related dementia. In these cases, neurodegeneration is due to the aggregation propensity and resultant toxic properties of the polyglutamine-containing proteins. We are interested in elucidating the underlying mechanisms of toxicity of the protein ataxin-3, in which a polyglutamine expansion is the genetic determinant for Machado-Joseph Disease (MJD), also referred to as spinocerebellar ataxia 3 (SCA3). To this end, we have developed a novel model for ataxin-3 protein aggregation, by expressing a disease-related polyglutamine-containing fragment of ataxin-3 in the genetically tractable body wall muscle cells of the model system C. elegans. Here, we demonstrate that this ataxin-3 fragment aggregates in a polyQ length-dependent manner in C. elegans muscle cells and that this aggregation is associated with cellular dysfunction. However, surprisingly, this aggregation and resultant toxicity was not influenced by aging. This is in contrast to polyglutamine peptides alone whose aggregation/toxicity is highly dependent on age. Thus, the data presented here not only describe a new polyglutamine model, but also suggest that protein context likely influences the cellular interactions of the polyglutamine-containing protein and thereby modulates its toxic properties.
Conflict of interest statement
Figures





Similar articles
-
Flanking domain stability modulates the aggregation kinetics of a polyglutamine disease protein.Protein Sci. 2011 Oct;20(10):1675-81. doi: 10.1002/pro.698. Epub 2011 Aug 18. Protein Sci. 2011. PMID: 21780213 Free PMC article.
-
Conformational targeting of fibrillar polyglutamine proteins in live cells escalates aggregation and cytotoxicity.PLoS One. 2009 May 28;4(5):e5727. doi: 10.1371/journal.pone.0005727. PLoS One. 2009. PMID: 19492089 Free PMC article.
-
Evidence for proteasome involvement in polyglutamine disease: localization to nuclear inclusions in SCA3/MJD and suppression of polyglutamine aggregation in vitro.Hum Mol Genet. 1999 Apr;8(4):673-82. doi: 10.1093/hmg/8.4.673. Hum Mol Genet. 1999. PMID: 10072437
-
Polyglutamine diseases: the special case of ataxin-3 and Machado-Joseph disease.Prog Neurobiol. 2011 Sep 15;95(1):26-48. doi: 10.1016/j.pneurobio.2011.06.007. Epub 2011 Jun 28. Prog Neurobiol. 2011. PMID: 21740957 Review.
-
Toward therapeutic targets for SCA3: Insight into the role of Machado-Joseph disease protein ataxin-3 in misfolded proteins clearance.Prog Neurobiol. 2015 Sep;132:34-58. doi: 10.1016/j.pneurobio.2015.06.004. Epub 2015 Jun 27. Prog Neurobiol. 2015. PMID: 26123252 Review.
Cited by
-
Rescue of ATXN3 neuronal toxicity in Caenorhabditiselegans by chemical modification of endoplasmic reticulum stress.Dis Model Mech. 2017 Dec 19;10(12):1465-1480. doi: 10.1242/dmm.029736. Dis Model Mech. 2017. PMID: 29061563 Free PMC article.
-
Models and mechanisms of repeat expansion disorders: a worm's eye view.J Genet. 2018 Jul;97(3):665-677. J Genet. 2018. PMID: 30027902 Free PMC article. Review.
-
A new Caenorhabditis elegans model of human huntingtin 513 aggregation and toxicity in body wall muscles.PLoS One. 2017 Mar 10;12(3):e0173644. doi: 10.1371/journal.pone.0173644. eCollection 2017. PLoS One. 2017. PMID: 28282438 Free PMC article.
-
Using C. elegans to discover therapeutic compounds for ageing-associated neurodegenerative diseases.Chem Cent J. 2015 Nov 26;9:65. doi: 10.1186/s13065-015-0143-y. eCollection 2015. Chem Cent J. 2015. PMID: 26617668 Free PMC article. Review.
-
An Unbiased High-Throughput Screen to Identify Novel Effectors That Impact on Cardiomyocyte Aggregate Levels.Circ Res. 2017 Sep 1;121(6):604-616. doi: 10.1161/CIRCRESAHA.117.310945. Epub 2017 Jun 27. Circ Res. 2017. PMID: 28655832 Free PMC article.
References
-
- Masino L, Musi V, Menon RP, Fusi P, Kelly G, et al. (2003) Domain architecture of the polyglutamine protein ataxin-3: a globular domain followed by a flexible tail. FEBS Lett 549: 21–25. - PubMed
-
- Ellisdon AM, Thomas B, Bottomley SP (2006) The two-stage pathway of ataxin-3 fibrillogenesis involves a polyglutamine-independent step. J Biol Chem 281: 16888–16896. - PubMed
-
- Chow MK, Ellisdon AM, Cabrita LD, Bottomley SP (2004) Polyglutamine expansion in ataxin-3 does not affect protein stability: implications for misfolding and disease. J Biol Chem 279: 47643–47651. - PubMed
-
- Paulson HL, Perez MK, Trottier Y, Trojanowski JQ, Subramony SH, et al. (1997) Intranuclear inclusions of expanded polyglutamine protein in spinocerebellar ataxia type 3. Neuron 19: 333–344. - PubMed
-
- McLeod CJ, O'Keefe LV, Richards RI (2005) The pathogenic agent in Drosophila models of ‘polyglutamine’ diseases. Hum Mol Genet 14: 1041–1048. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical